Abstract
Objective:
The aim of the study was to define pharmacodynamic markers for sudemycin D6, an experimental cancer drug that changes alternative splicing in human blood.
Methods:
Blood samples from 12 donors were incubated with sudemycin D6 for up to 24 hours, and at several time points total RNA from lymphocytes was prepared and the pre-messenger RNA (mRNA) splicing patterns were analyzed with reverse transcription-polymerase chain reaction.
Results:
Similar to immortalized cells, blood lymphocytes change alternative splicing due to sudemycin D6 treatment. However, lymphocytes in blood respond slower than immortalized cultured cells.
Conclusions:
Exon skipping in the DUSP11 and SRRM1 pre-mRNAs are pharmacodynamic markers for sudemycin D6 treatment and show effects beginning at 9 hours after treatment.
Document Type
Article
Publication Date
9-12-2017
Digital Object Identifier (DOI)
https://doi.org/10.1177/1177271917730557
Funding Information
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the NIH. (CA140474 and Clinical and Translational Science Award (CTSA) UL1TR001998); BD was supported by a RISE-DAAD fellowship.
Repository Citation
Thurman, Morgan; Van Doorn, Jacob; Danzer, Barbara; Webb, Thomas R.; and Stamm, Stefan, "Changes in Alternative Splicing as Pharmacodynamic Markers for Sudemycin D6" (2017). Molecular and Cellular Biochemistry Faculty Publications. 119.
https://uknowledge.uky.edu/biochem_facpub/119
Figure 1
Table 1.pdf (660 kB)
Table 1
Table 2.pdf (561 kB)
Table 2
Figure 2.pdf (684 kB)
Figure 2
Figure 3.pdf (726 kB)
Figure 3
Figure 4.pdf (425 kB)
Figure 4
Notes/Citation Information
Published in Biomarker Insights, v. 12, p. 1-6.
© The Author(s) 2017
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).